Moomoo AI 已提取核心信息
Clearmind Medicine Inc., a pharmaceutical company specializing in the development of psychedelic medicines, has filed a post-effective amendment to Form F-1 on Form F-3 with the Securities and Exchange Commission (SEC) on January 18, 2024. This filing is intended to convert two earlier registration statements into registration statements on Form F-3 and to file a combined prospectus. The registration statements in question were initially declared effective by the SEC on April 3, 2023, and September 14, 2023, respectively, and relate to the offering and sale of up to 1,047,384 Common Shares issuable upon the exercise of warrants. These shares are currently traded on the Nasdaq Capital Market under the symbol 'CMND.' The company has stated that the proceeds from the exercise of the warrants will be used for working capital, general corporate purposes, and potential strategic acquisitions.
Clearmind Medicine Inc., a pharmaceutical company specializing in the development of psychedelic medicines, has filed a post-effective amendment to Form F-1 on Form F-3 with the Securities and Exchange Commission (SEC) on January 18, 2024. This filing is intended to convert two earlier registration statements into registration statements on Form F-3 and to file a combined prospectus. The registration statements in question were initially declared effective by the SEC on April 3, 2023, and September 14, 2023, respectively, and relate to the offering and sale of up to 1,047,384 Common Shares issuable upon the exercise of warrants. These shares are currently traded on the Nasdaq Capital Market under the symbol 'CMND.' The company has stated that the proceeds from the exercise of the warrants will be used for working capital, general corporate purposes, and potential strategic acquisitions.
专门从事迷幻药物开发的制药公司Clearmind Medicine Inc. 已于2024年1月18日向美国证券交易委员会（SEC）提交了对F-3表格F-1的生效后修正案。该文件旨在将之前的两份注册声明转换为F-3表格上的注册声明，并提交合并的招股说明书。有关注册声明最初由美国证券交易委员会分别于2023年4月3日和2023年9月14日宣布生效，涉及发行和出售最多1,047,384股可在行使认股权证时发行的普通股。这些股票目前在纳斯达克资本市场上交易，股票代码为 “CMND”。该公司表示，行使认股权证的收益将用于营运资金、一般公司用途和潜在的战略收购。
专门从事迷幻药物开发的制药公司Clearmind Medicine Inc. 已于2024年1月18日向美国证券交易委员会（SEC）提交了对F-3表格F-1的生效后修正案。该文件旨在将之前的两份注册声明转换为F-3表格上的注册声明，并提交合并的招股说明书。有关注册声明最初由美国证券交易委员会分别于2023年4月3日和2023年9月14日宣布生效，涉及发行和出售最多1,047,384股可在行使认股权证时发行的普通股。这些股票目前在纳斯达克资本市场上交易，股票代码为 “CMND”。该公司表示，行使认股权证的收益将用于营运资金、一般公司用途和潜在的战略收购。
有用
没用